IBDEI06K ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8543,0)
 ;;=205.11^^60^586^28
 ;;^UTILITY(U,$J,358.3,8543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8543,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,8543,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,8543,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,8544,0)
 ;;=289.0^^60^586^52
 ;;^UTILITY(U,$J,358.3,8544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8544,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,8544,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,8544,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,8545,0)
 ;;=238.4^^60^586^103
 ;;^UTILITY(U,$J,358.3,8545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8545,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,8545,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,8545,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,8546,0)
 ;;=V58.61^^60^586^124
 ;;^UTILITY(U,$J,358.3,8546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8546,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,8546,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,8546,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,8547,0)
 ;;=282.49^^60^586^116
 ;;^UTILITY(U,$J,358.3,8547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8547,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,8547,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,8547,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,8548,0)
 ;;=289.89^^60^586^18
 ;;^UTILITY(U,$J,358.3,8548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8548,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,8548,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,8548,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,8549,0)
 ;;=238.79^^60^586^85
 ;;^UTILITY(U,$J,358.3,8549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8549,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,8549,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,8549,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,8550,0)
 ;;=287.30^^60^586^104
 ;;^UTILITY(U,$J,358.3,8550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8550,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,8550,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,8550,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,8551,0)
 ;;=288.09^^60^586^8
 ;;^UTILITY(U,$J,358.3,8551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8551,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,8551,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,8551,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,8552,0)
 ;;=284.81^^60^586^15
 ;;^UTILITY(U,$J,358.3,8552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8552,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,8552,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,8552,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,8553,0)
 ;;=284.89^^60^586^14
 ;;^UTILITY(U,$J,358.3,8553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8553,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,8553,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,8553,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,8554,0)
 ;;=284.9^^60^586^12
 ;;^UTILITY(U,$J,358.3,8554,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8554,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,8554,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,8554,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,8555,0)
 ;;=289.84^^60^586^117
 ;;^UTILITY(U,$J,358.3,8555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8555,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,8555,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,8555,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,8556,0)
 ;;=204.02^^60^586^3
 ;;^UTILITY(U,$J,358.3,8556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8556,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,8556,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,8556,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,8557,0)
 ;;=204.12^^60^586^25
 ;;^UTILITY(U,$J,358.3,8557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8557,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,8557,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,8557,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,8558,0)
 ;;=204.21^^60^586^112
 ;;^UTILITY(U,$J,358.3,8558,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8558,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,8558,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,8558,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,8559,0)
 ;;=204.20^^60^586^113
 ;;^UTILITY(U,$J,358.3,8559,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8559,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,8559,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,8559,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,8560,0)
 ;;=204.22^^60^586^114
 ;;^UTILITY(U,$J,358.3,8560,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8560,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,8560,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,8560,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,8561,0)
 ;;=203.02^^60^586^100
 ;;^UTILITY(U,$J,358.3,8561,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8561,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,8561,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,8561,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,8562,0)
 ;;=205.02^^60^586^6
 ;;^UTILITY(U,$J,358.3,8562,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8562,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,8562,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,8562,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,8563,0)
 ;;=205.12^^60^586^27
 ;;^UTILITY(U,$J,358.3,8563,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8563,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,8563,1,5,0)
 ;;=5^CML in Relapse
 ;;^UTILITY(U,$J,358.3,8563,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,8564,0)
 ;;=V10.91^^60^586^63
 ;;^UTILITY(U,$J,358.3,8564,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8564,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,8564,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,8564,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,8565,0)
 ;;=V10.91^^60^586^72
 ;;^UTILITY(U,$J,358.3,8565,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8565,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,8565,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,8565,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,8566,0)
 ;;=465.9^^60^587^73
 ;;^UTILITY(U,$J,358.3,8566,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8566,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,8566,1,5,0)
 ;;=5^Uri
 ;;^UTILITY(U,$J,358.3,8566,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,8567,0)
 ;;=462.^^60^587^60
 ;;^UTILITY(U,$J,358.3,8567,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8567,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,8567,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,8567,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,8568,0)
 ;;=466.0^^60^587^3
 ;;^UTILITY(U,$J,358.3,8568,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8568,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,8568,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,8568,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,8569,0)
 ;;=112.1^^60^587^78
 ;;^UTILITY(U,$J,358.3,8569,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8569,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,8569,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,8569,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,8570,0)
 ;;=616.0^^60^587^13
 ;;^UTILITY(U,$J,358.3,8570,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8570,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,8570,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,8570,2)
 ;;=^21925
 ;;^UTILITY(U,$J,358.3,8571,0)
 ;;=599.0^^60^587^74
 ;;^UTILITY(U,$J,358.3,8571,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8571,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,8571,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,8571,2)
 ;;=UTI^124436
 ;;^UTILITY(U,$J,358.3,8572,0)
 ;;=460.^^60^587^45
 ;;^UTILITY(U,$J,358.3,8572,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8572,1,4,0)
 ;;=4^460.
 ;;^UTILITY(U,$J,358.3,8572,1,5,0)
 ;;=5^Nasopharyngitis, Acute
 ;;^UTILITY(U,$J,358.3,8572,2)
 ;;=^26543
 ;;^UTILITY(U,$J,358.3,8573,0)
 ;;=372.30^^60^587^14
 ;;^UTILITY(U,$J,358.3,8573,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8573,1,4,0)
 ;;=4^372.30
 ;;^UTILITY(U,$J,358.3,8573,1,5,0)
 ;;=5^Conjunctivitis
 ;;^UTILITY(U,$J,358.3,8573,2)
 ;;=^27546
 ;;^UTILITY(U,$J,358.3,8574,0)
 ;;=595.9^^60^587^15
 ;;^UTILITY(U,$J,358.3,8574,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8574,1,4,0)
 ;;=4^595.9
 ;;^UTILITY(U,$J,358.3,8574,1,5,0)
 ;;=5^Cystitis
 ;;^UTILITY(U,$J,358.3,8574,2)
 ;;=^30304
 ;;^UTILITY(U,$J,358.3,8575,0)
 ;;=110.1^^60^587^16
 ;;^UTILITY(U,$J,358.3,8575,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8575,1,4,0)
 ;;=4^110.1
 ;;^UTILITY(U,$J,358.3,8575,1,5,0)
 ;;=5^Dermatophytosis Nail
 ;;^UTILITY(U,$J,358.3,8575,2)
 ;;=^33173
 ;;^UTILITY(U,$J,358.3,8576,0)
 ;;=562.11^^60^587^17
 ;;^UTILITY(U,$J,358.3,8576,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8576,1,4,0)
 ;;=4^562.11
 ;;^UTILITY(U,$J,358.3,8576,1,5,0)
 ;;=5^Diverticulitis
 ;;^UTILITY(U,$J,358.3,8576,2)
 ;;=^270274
 ;;^UTILITY(U,$J,358.3,8577,0)
 ;;=424.90^^60^587^18
 ;;^UTILITY(U,$J,358.3,8577,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8577,1,4,0)
 ;;=4^424.90
 ;;^UTILITY(U,$J,358.3,8577,1,5,0)
 ;;=5^Endocarditis
 ;;^UTILITY(U,$J,358.3,8577,2)
 ;;=^40327
 ;;^UTILITY(U,$J,358.3,8578,0)
 ;;=604.90^^60^587^19
 ;;^UTILITY(U,$J,358.3,8578,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8578,1,4,0)
 ;;=4^604.90
 ;;^UTILITY(U,$J,358.3,8578,1,5,0)
 ;;=5^Epididymitis
 ;;^UTILITY(U,$J,358.3,8578,2)
 ;;=^86178
 ;;^UTILITY(U,$J,358.3,8579,0)
 ;;=707.15^^60^587^21
 ;;^UTILITY(U,$J,358.3,8579,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8579,1,4,0)
 ;;=4^707.15
 ;;^UTILITY(U,$J,358.3,8579,1,5,0)
 ;;=5^Foot Ulcer
 ;;^UTILITY(U,$J,358.3,8579,2)
 ;;=^322148
 ;;^UTILITY(U,$J,358.3,8580,0)
 ;;=558.9^^60^587^22
 ;;^UTILITY(U,$J,358.3,8580,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8580,1,4,0)
 ;;=4^558.9
 ;;^UTILITY(U,$J,358.3,8580,1,5,0)
 ;;=5^Gastroenteritis
 ;;^UTILITY(U,$J,358.3,8580,2)
 ;;=^87311
 ;;^UTILITY(U,$J,358.3,8581,0)
 ;;=054.71^^60^587^33
 ;;^UTILITY(U,$J,358.3,8581,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8581,1,4,0)
 ;;=4^054.71
